OncoMatch/Clinical Trials/NCT05983237
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Is NCT05983237 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Fluzoparib Camrelizumab Temozolomide for melanoma.
Treatment: Fluzoparib Camrelizumab Temozolomide — The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Biomarker criteria
Required: HR mutation/alteration
Required: SF3B1 mutation/alteration
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: parp inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05983237 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior parp inhibitor disqualifies patients from enrollment.
Does this trial require HR?
Yes, HR mutation/alteration is a required biomarker for enrollment.
Does this trial require SF3B1?
Yes, SF3B1 mutation/alteration is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages